SCHEMBL17523488

SCHEMBL17523488

Cc1ccc(NC(=O)c2ccnc(C(C)(F)F)c2)cc1-c1nc(N2CCOCC2)c2[nH]ccc2n1

nearest known ligand 0.84

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 20/20 0.84
BRAF P15056 20/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17523485 0.97 RAF1 (0.84) RAF1BRAF
SCHEMBL17523482 0.95 BRAF (0.81) RAF1BRAF
SCHEMBL16094188 0.91 BRAF (1.00) RAF1BRAF
SCHEMBL16094271 0.87 RAF1 (1.00) RAF1BRAF
SCHEMBL16121811 0.81 BRAF (0.65) RAF1BRAF
SCHEMBL17523509 0.80 BRAF (0.83) RAF1BRAF
SCHEMBL16121759 0.80 BRAF (1.00) RAF1BRAF
SCHEMBL20008474 0.80 BRAF (0.63) RAF1BRAF
SCHEMBL16121521 0.79 RAF1 (1.00) RAF1BRAF
SCHEMBL16103154 0.79 RAF1 (1.00) RAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10709712-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2020-07-14 US disclosed
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-06-13 US disclosed
US-10245267-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2019-04-02 US disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 US disclosed
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2017-09-14 US disclosed
US-9694016-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2017-07-04 US disclosed
US-9694016-B2 Biaryl amide compounds as kinase inhibitors NOVARTIS AG (CH) 2017-07-04 US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 US disclosed
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10709712-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885
US-20170260207-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885
US-20190175606-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885
US-20160038504-A1 BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885
US-10245267-B2 Biaryl amide compounds as kinase inhibitors BRAF, RAF1, NRAS RAF1 2/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.